You better get in line now, a brand new COVID Treatment is here. Bamlanivimab, a monoclonal antibody therapy, was authorized for emergency use by the FDA near the end of 2020 and may prove to be an effect combatant against COVID symptoms and rising hospitalizations.
What is BAM Treatment?
Bamlanivimab, more commonly known as BAM, is a neutralizing antibody drug used to help treat COVID-19. BAM contains man-made antibodies, similar to those found in recovered COVID-19 patients, that try to limit the amount of virus currently in your body, in turn giving your body more time to produce its own virus-fighting antibodies and eventually rid itself of the COVID virus.
Some trials have found the drug may be successful in limiting the COVID virus in patients who are within 10 days of their first symptoms. While BAM is still being studied, the drug was authorized for emergency use by the FDA and scientists believe after clinical trials that BAM can prevent the need of someone needing a hospital.
Who is it for?
The FDA has authorized the use of BAM to treat mild-to-moderate cases of COVID-19 in both pediatric and adult patients. However, there are stipulations. Prospective patients must be high-risk for severe COVID-19 symptoms or hospitalization and cannot have already been hospitalized due to COVID-19 or received the COVID vaccine.
Should I Consider BAM Treatment?
If you are COVID positive and over 65, or positive with a serious chronic health condition, BAM may be a treatment path you need to seriously consider.
“Receiving the monoclonal infusion if you are at high risk for progression of the disease may prevent the need for hospitalization.” – Dr. Mousumi Som, OSU Medical Center Chief of Staff
For qualifying, severe-risk patients, BAM treatment may help keep you out of the hospital and avoid serious symptoms, getting you back to your normal self—quicker. However, as always, if you are considering BAM treatment first talk with your primary care physician and together you can decide if BAM treatment is the right path for you.